Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
Pharmacokinetic factors affecting airway selectivity of inhaled steroids – role of prodrug conversion and absorption Source: Eur Respir J 2004; 24: Suppl. 48, 347s Year: 2004
Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500μg to 1000μg are dose-linear in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004
Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019
Pharmacokinetic factors affecting airway selectivity of inhaled steroids - role of intracellular esterification Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Effects of long acting β2-agonist, sustained-release theophylline and their combination on exercise parameters in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 287s Year: 2002
Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Source: Eur Respir J 2006; 28: 1042-1050 Year: 2006
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018
Pronounced tissue and plasma protein binding of ciclesonide is responsible for reduced pharmacodynamic potency in the lung Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Fevipiprant (QAW039) demonstrates safety, tolerability and consistent PK at high oral doses Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Effects of different serum theophylline concentrations on erythropoietin and hematocrit levels in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 422s Year: 2003
Pharmacokinetic (PK) and pharmacodynamic (PD) data for inhaled and intranasal corticosteroids (CS) reassessed using a physiological PK/PD model Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Pharmacokinetic characteristics of roflumilast and its active metabolite roflumilast-N-oxide are not affected by food intake Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone Source: Eur Respir J, 53 (1) 1801060; 10.1183/13993003.01060-2018 Year: 2019
The role of serum rifampicin level on antituberculosis treatment outcome Source: Eur Respir J 2006; 28: Suppl. 50, 848s Year: 2006